On May 1, 2023, Day One Biopharmaceuticals, Inc. announced the appointment of Dr. Samuel Blackman, the Companys Co-founder and current Chief Medical Officer, to the position of Head of Research and Development of the Company, effective as of May 1, 2023. Biographical information for Dr. Blackman may be found in the Companys definitive proxy statement relating to its 2023 Annual Meeting of Stockholders, filed with the U.S. Securities and Exchange Commission (the SEC) on April 28, 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.18 USD | +0.94% | +1.28% | +10.99% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.99% | 1.4B | |
+32.73% | 50.85B | |
+0.07% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.83% | 26.11B | |
-22.26% | 19.13B | |
+8.37% | 13.05B | |
+27.21% | 12.16B | |
+24.42% | 12.08B |
- Stock Market
- Equities
- DAWN Stock
- News Day One Biopharmaceuticals, Inc.
- Day One Biopharmaceuticals, Inc. Appoints Samuel Blackman as Head of Research and Development